What is Parse Biosciences?
Parse Biosciences is a global life sciences company that develops scalable and accessible single-cell sequencing solutions. The company's pioneering Evercode platform and associated tools enable researchers to perform transcriptomic and immune profiling without the need for specialized instruments. This technology supports critical discoveries in areas such as cancer treatment, tissue repair, stem cell therapy, and immunology. Headquartered in Seattle, Parse Biosciences partners with laboratories and organizations worldwide to expand the usage of its technologies and support breakthroughs in biomedical research.
How much funding has Parse Biosciences raised?
Parse Biosciences has raised a total of $98.5M across 3 funding rounds:
Other Financing Round
$7M
Series B
$41.5M
Series C
$50M
Other Financing Round (2021): $7M with participation from Bioeconomy Capital
Series B (2022): $41.5M led by Marshall Wace, Logos Capital, Bioeconomy Capital, Janus Henderson Group, and Soleus Capital
Series C (2023): $50M supported by Bioeconomy Capital, Janus Henderson Group, Soleus Capital, Sahsen Ventures, Marshall Wace, and Saras Capital
Key Investors in Parse Biosciences
Bioeconomy Capital
Bioeconomy Capital is an early-stage venture capital firm that specializes in companies that are laying the foundation for the rapidly expanding bioeconomy. We expect advances in biology to profoundly improve the human condition and contribute to the global economy. Bioeconomy Capital invests primarily in: (i) technologies that enable biological engineering and production; and (ii) companies that use those technologies to produce goods and services.
Janus Henderson Group
Janus Henderson is a global investment management firm that provides a broad range of investment solutions and advisory services to institutional investors, financial professionals, and individual clients. The company is focused on helping clients achieve their financial objectives through disciplined investment strategies, in-depth research, and a commitment to delivering strong long-term outcomes. By combining global market expertise with a client-centric approach, it seeks to create investment solutions that address diverse financial goals and evolving market conditions.
Soleus Capital
Soleus Capital is a healthcare investment firm that specializes in innovative life sciences sectors, including biotech, medtech, diagnostics, and genomics. The firm invests across the healthcare lifecycle, targeting both developmental-stage and commercial companies. Their focus is on advancing healthcare solutions through strategic investments in cutting-edge technologies. Soleus Capital aims to support the growth of companies that are shaping the future of healthcare.
What's next for Parse Biosciences?
With its recent major enterprise-level funding, Parse Biosciences is strategically positioned to further scale its operations and enhance its innovative single-cell sequencing technologies. The company's focus on providing accessible solutions for transcriptomic and immune profiling is expected to drive further advancements in critical research areas like oncology and immunology. Continued investment will likely fuel product development, market expansion, and strategic partnerships, solidifying Parse Biosciences' role in accelerating biomedical discoveries and improving human health outcomes.
See full Parse Biosciences company page
